Delhi High Court Records Interim Arrangement In Novo Nordisk–Torrent Pharma Patent Dispute Over Semaglutide

The Delhi High Court has recorded an interim arrangement between Danish pharmaceutical company Novo Nordisk and Torrent Pharmaceuticals Limited in a patent infringement suit concerning semaglutide, a compound used in the popular diabetes and weight-loss drug Ozempic.

Justice Tushar Rao Gedela on March 20, 2026, recorded that the parties had agreed to an interim arrangement under which the Torrent would ensure that the concentration of a specific chemical component in its product does not fall within the range claimed under the Danish Pharms's patent.

Recording the consensus, the court noted that “both the parties have agreed to the following directions as an interim arrangement” and clarified that the arrangement was “without prejudice to rights and contentions of any of the parties”.

Novo Nordisk contended that it holds patent IN 325669, which claims a range of 0.6 to 2.1 mmol of the salt N-(8-(2-hydroxybenzoyl)amino) caprylic acid (SNAC).

The company had filed an application seeking “ex-parte ad-interim injunction” against the defendant.

Torrent Pharmaceuticals told the court that its indigenous product does not infringe the claims of the patent. In an affidavit filed by its Chief Operating Officer Hasmukh Patel, the company stated that the “indigenous product of the Defendant is not infringing the claims of the patent IN 325669”.

The affidavit further stated that the defendant's product under CTRI number CTRI/2025/05/087221 has N-(8-(2-hydroxybenzoyl) amino) caprylic acid [SNAC] at 160 mg, which is 0.53 mmol, “thereby falling outside the claimed range”.

Torrent also stated that “the Defendant is willing to keep accounts of sales of their product”.

After hearing the parties, the Court recorded the interim arrangement agreed between them.

Under the arrangement, the defendant agreed to manufacture Semaglutide (Oral Tablet) 3 mg, 7 mg and 14 mg under the brand names “Semalix” and “Sembolic” comprising SNAC at 0.53 mmol and that it “would not breach the range of 0.6 to 2.1 mmol claimed under the claim 1 of the plaintiffs' patent IN325669”.

The Court further recorded that the defendant shall not breach the said range for any product, including the aforesaid products, “for domestic as well as export purposes”.

The defendant also assured that it would “handover a sample each of Semaglutide (Oral Tablet) 3mg, 7mg and 14 mg under Brand names 'Semalix' and 'Sembolic'” to the plaintiffs' counsel.

The court directed that the affidavit of the defendant's authorised representative be formally filed and recorded that the defendant “shall file the said affidavit within next the three working days ”.

The Court granted 30 days to Torrent to file its written statement and listed the matter on April 24, 2026, for further hearing.